Growth stimulation expressed gene 2 (ST2): Clinical research and application in the cardiovascular related diseases

Jinchao Chen, Peng Xiao, Dan Song, Dewei Song, Zhi Chen, Hongmei LiFrontiers in Cardiovascular Medicine 2022 · DOI

Abstract

As an interleukin (IL)-1 receptor family member, scientists found that when circulating soluble growth stimulation expressed gene 2 (sST2) is low, its ligand, IL-33, will bind to ST2L to exert protective effects on various types of cells. On the other hand, competitive binding of IL-33 occurs when sST2 concentrations are increased, followed by a reduction in the amount available for cell protection. Based on this mechanism, the usage of sST2 is to identify the population of high-risk patients with cardiovascular disease. In recent years, the role of serum sST2 in the occurrence, diagnosis, prognosis, and treatment of cardiovascular diseases has been gradually accepted by doctors. This manuscript systemically reviews the biological functions and applications of sST2 in disease diagnosis and treatment, especially for cardiovascular diseases. In clinical testing, since IL-33 can negatively impact sST2 measurement accuracy, the properties of current assay kits have been summarized and discussed to provide a clear view of the clinical chemistry results. Although sST2 is a promising biomarker, there are few quantitative approaches available for clinical testing. In this context, a mass spectrometry (MS)-based approach might be an option, as this is a powerful analytical tool to distinguish structurally related molecules in the matrix and decrease false-positive results in clinical testing. Moreover, approaches developed based on MS would be an ideal way to further study sST2 standardization.

The Challenge of Cardiovascular Risk Stratification

Cardiovascular disease (CVD) remains a leading cause of global mortality, necessitating precise biomarkers for risk stratification. While traditional markers like natriuretic peptides (BNP/NT-proBNP) reflect heart strain, they do not always capture the underlying processes of cardiac fibrosis and remodeling. Soluble ST2 (sST2) has emerged as a potent "decoy receptor" biomarker that predicts poor outcomes in heart failure (HF) and coronary artery disease (CAD) by blocking cardioprotective signaling. Although recognized by major guidelines (ACCF/AHA), sST2 faces a significant "translation gap" due to inconsistent clinical assay results.

Biological Mechanisms of ST2 Isoforms

The ST2 gene (IL1RL1) produces four distinct isoforms via alternative splicing: the membrane-bound ST2L, the soluble sST2, and the less common ST2V and ST2LV.

Gene structures and cellular localization of ST2 isoforms (ST2L, sST2, ST2V, and ST2LV).

The primary mechanism involves the IL-33/ST2 signaling pathway. ST2L transmits protective signals when bound to its ligand, IL-33. However, sST2 acts as a decoy, "soaking up" IL-33 and preventing it from binding to ST2L on myocardial cells. This leaves the heart vulnerable to hypertrophy, fibrosis, and apoptosis. Because sST2 is also expressed in the lungs, gut, and immune cells, its specificity for the heart can be low, yet its prognostic value remains high when combined with other markers.

Clinical Utility and Prognostic Value

Clinical evidence from large-scale cohorts, including a meta-analysis of 12,690 patients with acute coronary syndrome, highlights sST2 as a superior prognostic tool.

  • Heart Failure: An upper reference limit of 35 ng/ml is a critical threshold. Doubling a patient's sST2 level is associated with a 25–30% increase in the risk of cardiovascular death or hospitalization.
  • Coronary Artery Disease: In stable CAD, elevated sST2 independently predicts long-term all-cause mortality.
  • Comorbidities: sST2 levels correlate with diastolic dysfunction in Type 2 Diabetes and left ventricular hypertrophy in hypertensive patients.

Overcoming the Standardization Gap

Current clinical assays, primarily ELISAs, often yield non-comparable results due to "epitope masking," where IL-33 blocks the antibody from detecting sST2. There is currently no international primary reference material or reference measurement procedure for sST2.

To achieve the analytical "gold standard," the field must move toward Mass Spectrometry (MS). Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) using isotopic dilution can distinguish between free and bound sST2, providing the absolute quantification required for global clinical standardization and reliable risk assessment.

Summary updated

Abstract

As an interleukin (IL)-1 receptor family member, scientists found that when circulating soluble growth stimulation expressed gene 2 (sST2) is low, its ligand, IL-33, will bind to ST2L to exert protective effects on various types of cells. On the other hand, competitive binding of IL-33 occurs when sST2 concentrations are increased, followed by a reduction in the amount available for cell protection. Based on this mechanism, the usage of sST2 is to identify the population of high-risk patients with cardiovascular disease. In recent years, the role of serum sST2 in the occurrence, diagnosis, prognosis, and treatment of cardiovascular diseases has been gradually accepted by doctors. This manuscript systemically reviews the biological functions and applications of sST2 in disease diagnosis and treatment, especially for cardiovascular diseases. In clinical testing, since IL-33 can negatively impact sST2 measurement accuracy, the properties of current assay kits have been summarized and discussed to provide a clear view of the clinical chemistry results. Although sST2 is a promising biomarker, there are few quantitative approaches available for clinical testing. In this context, a mass spectrometry (MS)-based approach might be an option, as this is a powerful analytical tool to distinguish structurally related molecules in the matrix and decrease false-positive results in clinical testing. Moreover, approaches developed based on MS would be an ideal way to further study sST2 standardization.
BibTeX
@inproceedings{chen2022growth,
  author = {Jinchao Chen and Peng Xiao and Dan Song and Dewei Song and Zhi Chen and Hongmei Li},
  title = {{Growth stimulation expressed gene 2 (ST2): Clinical research and application in the cardiovascular related diseases}},
  booktitle = {Frontiers in Cardiovascular Medicine},
  year = {2022},
  doi = {10.3389/fcvm.2022.1007450},
}
Figure